The epitopes Tn and sialosyl-Tn are expressed on erythrocytes of individuals with a very rare blood group, who often suffer from "Tn syndrome." We surveyed expression of Tn and sialosyl-Tn in normal blood cells, malignant transformed cells, and progenitor stem cells from bone marrow (BM). An anti-Tn antibody, IE3, and an anti-sialosyl-Tn antibody, TKH2, were used in this study. TKH2 reacted with erythroblasts, B cells, and a subset of CD4+ cells, but not with erythrocytes. Erythroblastic cell lines (K562, HEL, and UT7IEPO) and B-cell lines (Daudi, Raji, and B-cell lines transformed by Epstein-Barr virus) showed reactivity to TKH2. Similar results from the reactivity of TKH2 with transformed cells from leukemia patients and lymphoma patients were obtained; TKH2 reacted with blasts from erythroleukemia (M6; for 4 of 4 cases) and with lymphocytes from B-cell chronic lymphocytic leukemia (3
HOMSEN AND HIS ASSISTANT Friedenreich no-
ticed by chance that a blood specimen typed as group 0 on one day was converted to type AB on the next day.','
This phenomenon was considered to be caused by incidental contamination by bacterial or viral sialidase, and by resulting exposure of a cryptic antigen reactive with antibodies widely distributed in all blood (polyagglutinin). The epitope of this cryptic antigen (later called T) was identified as GalPI + 3GalNAca-linked to 0-Ser/Thr of a polypeptide with defined structure."' In 1957, Moreau et al' described a very rare group with reactivity similar to T-expressing blood. However, the new epitope had specificity obviously different from that of T and was termed T-nouvelle (new T;
Tn for short). Blood group Tn is found in less than 1 of every 100,000 people and is often associated with Tn syndrome (hemolytic anemia, leukopenia, thrombocytopenia, etc). This syndrome is thought to be caused by anti-Tn antibodies universally present in human sera. Aberrant expression of Tn may cause an autoimmune ~y n d r o m e .~ Blood of 3). B-cell lymphoma (5 of 5). and CD4+ adult T-cell leukemia (4 of 4). but did not react with blasts from acute myeloid leukemia (MO to M5; 0 of 22) or acute lymphoid leukemia (B-lymphoid leukemia, 0 of 11; T-lymphoid leukemia, 0 of 2; undifferentiated leukemia, 0 of 1). IE3 did not react with all of the tested cells. CD2-CD1 9-TKH2+ normal BM cells (BMC) contained blasts and various maturation stages of erythroblasts. The TKH2+ cells produced a large number of colony-forming unit-erythroid (CFU-E) colonies, whereas they produced a small number of burstforming unit-erythroid colonies and CFU-granulocytemacrophage colonies. CD34+ normal BMC did not express Tn and sialosyl-Tn. These findings suggest that sialosyl-Tn expresses in CFU-E to erythroblasts. cells of Tn individuals express both Tn and sialosyl-Tn (NeuAca2 + 6GalNAcaI + o-Se~-/Thr).~ Tn antigen is regarded as an A-cross-reacting antigen6 highly expressed in a large variety of human cancers,' and sialosyl-Tn has also been identified as a typical tumor-associated antigen. ' Recently, we have shown that lacto-series type 2 chain antigens are expressed by neutrophils, monocytes, granulocyte-macrophage-committed cells, and leukemic myeloblasts but are not expressed by CD34+ normal progenitor cells.' In that study, a erythroblastic cell line, K562, highly expressed the sialosyl-Tn antigen. Therefore, we have extended that work and shown expression of the sialosyl-Tn antigen in colony-forming unit-erythroid (CFU-E), erythroblasts, B cells, and a subset of CD4+ cells, but not in erythrocytes or CD34' bone marrow cells (BMC).
MATERIALS AND METHODS

Cells and cell lines.
Various leukemic cell lines were kindly donated by Dr J. Minowada (Fujisaki Cell Center, Hayashibara Biochemical Laboratory, Okayama, Japan), Dr T. Kasahara (Department of Biology and Parasitology, Jichi Medical School), and Dr N. Komatsu (Division of Hematology, Department of Medicine, Jichi Medical School). The cell lines used in this study were as follows: a promyelocytic cell line, HL-60; a monoblastic cell line, THPI; erythroblastic cell lines, K562, HEL, and UT7/EPO; megakaryoblastic cell lines, UT7 and CMK; pre-B-cell lines, NALM18 and KM3; B-cell lines, Raji and Daudi; and a T-cell line, MOLT4. Two B-cell lines transformed by Epstein-Barr virus (EBV-B) were established in our laboratory. All cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS; Flow Laboratories, McLean, VA) at 37°C in a 5% CO2 incubator. Peripheral blood or BM blood was obtained from healthy volunteers and patients. Lymph nodes of patients with lymphoma were also collected after lymph node biopsy. Mononuclear cells were selected by gradient centrifugation on pyogen-tested Lymphoprep (Nycomed, Oslo, Norway). The isolated mononuclear cells contained more than 80% of leukemic cells or lymphoma cells. Leukemia was diagnosed according to the French-American-British classification." Normal erythroblasts were obtained from burst-forming unit-erythroid (BFU-E) as described below. More than 20 colonies of BFU-E were picked up and collected in each volunteer. Dual-staining. This procedure was performed as previously described? Mononuclear cells from three adult BM samples were independently pelleted for staining with MoAbs. Cells were incubated with TKHZ or IE3 for 30 minutes at 4"C, and subsequently with FITC-conjugated antimouse IgG. They were then stained with allophycocyanin (APC)-conjugated 4A1 (CD34; Nichirei CO, Tokyo, Japan).13 The mononuclear cells were also dually stained with APCconjugated 4A1 and phycoerythrin (PE)-conjugated J5 (CD10; Coulter). Mononuclear cells from three adult peripheral blood samples were dually stained with TKH2 and one of the mouse MoAbs. The cells were incubated with TKHZ for 30 minutes at 4"C, subsequently with FITC-conjugated antimouse IgG; Then, they were stained with one of the following MoAbs: PE-conjugated Leu12 (CD 19; Becton Dickinson), APC-conjugated Leu3k (CD4; Becton Dickinson), PE-conjugated Leu2a (CD8; Becton Dickinson), PEconjugated 4B4 (CD29; Coulter), or PE-conjugated 2H4 (CD45RA; Coulter). Stained cells were analyzed on FACStaP'"' (Becton Dickinson). Results were analyzed after setting a gate around the lymphoid/blast cell population. Multiparameter data were collected and analyzed using FACS-DESK (version l .2) run on a Digital Micro VAX-I1 GPX (Digital Equipment COT, Maynard, MA) as previously described.' Fluorescence intensity of individual cells was measured as relative fluorescence units. Data from more than 50,000 mononuclear cells were collected. In other experiments, normal erythroblasts were obtained from five healthy volunteers as described above. AB-type erythrocytes were obtained from three healthy volunteers. The erythroblasts and the erythrocytes were dually stained with TKH2 and PE-conjugated antiglycophorin A. The stained cells were analyzed using the Spectrum I11 flow cytometer.
Isolation of TKH2+ cells. Anti-CD2-coated microspheres and anti-CD19-coated microspheres (Dynal, Great Neck, NY) were washed twice in RPMI-I640 medium supplemented with 10% FCS (RPMI/IO% FCS), and 0.5 mL of I O pg/mL TKH2 was incubated overnight at 4°C with 0.05 mL of antimouse IgGl(Fc)-coated microspheres (Dynal). The TKHZ-coated microspheres were washed 3 times in RPMI/ 10% FCS to remove free TKHZ. BM mononuclear cells were obtained from five healthy volunteers. The cells were washed twice in RPMI/ 10% FCS and cultured overnight at 1 X IO6/ mL at 37°C in a 5% CO2 incubator. Nonadherent cells were collected and resuspended at 1 X 107/mL in RPMI/IO% FCS. The anti-CD2-coated microspheres and the anti-CD19-coated microspheres were added to the cells at a ratio of cells to magnetic beads of I: IO. The mixture was incubated, shaken for 30 minutes at 4"C, and then the bead-coated cells were removed with a magnetic particle concentrator (Dynal). The unbound cells were incubated with the TKH2-coated microspheres at a ratio of cells to magnetic beads of 1:3 for 30 minutes at 4°C. Cells bound to TKH2 were collected and mixed with 2 U (20 pL) of DETACHaBEAD (Dynal) to remove the cells from the beads. The mixture was incubated at room temperature for 60 minutes, and then the TKH2' cells were released from the beads. The isolated cells were counted, and viability was tested by trypan-blue dye exclusion test, which showed more than 90% viability. The cells were stained with Wright-Giemsa and analyzed with expression of MY7 (CD13), LeuMl (CD1 5; Becton Dickinson), HPCAl (CD34), P2 (CD4la), and glycophorin A. The ability of the cells to form colonies in methylcellulose culture was performed.
Colony assay. Methylcellulose cultures were performed as previously described.' Briefly, cells were incubated in 1 mL of 1.2% methylcellulose (Aldrich Chemical, Milwaukee, WI), 30% FCS, 1% deionized bovine serum albumin (Sigma), 5 X mol/L 2-mercaptoethanol (Sigma), 5% phytohemaggulutin-activated lymphocyte-conditioned medium, 2 U/mL recombinant human erythropoietin (Chugai Pharmaceutical, Tokyo, Japan), and I% Lglutamin. The cultures were incubated for 14 days at 37'C in a 5% CO2 incubator. On day 7 of culture, the number of CFU-E was scored based on morphology of the colony (small, compact, and slightly reddish colony). CFU-E colonies were defined as aggregates consisting of 8 or more cells. On day 14 of culture, the number of BFU-E, CFU-granulocyte-macrophage (CFU-GM), CFU-macro- phage (CFU-M), and CFIJ~granulocyte-n~acrophagc-erythroid (CFIJ-Mix) was scored. Colonies were dctincd as aggregates consisting of 40 or more cells.
RESULTS
RcwcfivI'Iy ~' i l f 7
nt)rmulpcvi~)hcvu/ hlood r d l s . TKH2 reacted with a small population ofperipheral blood lymphocytes but not with neutrophils, monocytes, platelets, or erythrocytes (Table 2 ). IE3 did not react with all of these cells. Dual-staining showed that TKH? reactcd with CD19' cells and subsets of CD4+ and CD29+ cells but did not react with CD8 ' and CD45RAt cells (Fig l) . Table 2, TKH2 reacted with erythroblasts. Most of erythroblasts expressed both sialosyl-Tn and glycophorin A, whereas crythrocytes expressed glycophorin A alone (Fig 2) . TKH2 did not react with CD34' BMC, although it did react with a small population of CDlO' cells (Fig 3) . IE3 did not react with the erythroblasts or the CD34' cells (data not shown). pre-B-cell lines (NALM18 and KM3), and one T-cell line (MOLT4). Subsequently, reactivity with various transformcd cells from patients was examined. As shown in Table 3 and Fig 5 , TKH2 reacted with leukemic blasts from the M6-type of acute myeloid leukemia (AML,; for 4 of 4 cases), whereas it reacted with none of the leukemic myeloblasts, promyelocytes, myclomonoblasts, or monoblasts ( 0 of 22). TKH2 reacted with CD10 CD I9 'CD20iCD5+ lymphocytes from chronic lymphocytic leukemia (CLL: for 3 of 3 cases) and CDI9'C-D20'smIg' lymphocytes from non-Hodgkin's lymphoma (NHL; 5 of 5), but not with lymphoblasts from acute lymphoid leukemia (ALL; 0 of 14). In addition, TKH2 reacted with CD4' lymphocytes from adult T-cell leukemia (ATL; 4 of 4), although the reactivity was borderline in 2 cases. None of the leukemic cell lines or the patient-derived transformed cells reacted with IE3.
Rcuctivily wirh normal BM('. As shown in
Isolution c!/ 'T'K112 ' B M C CD2-CD I9 TKH2' cells
were prepared from normal BMC as described in the Materials and Mcthods. The isolated cells contained erythroid cells at various stages of maturation, eg, proerythroblasts, basophilic erythroblasts, and early or late polychromatophilic erythroblasts (Fig 6) . In addition, a few blast-like cells existed. Flow cytometric analyses showed that more than 70% of the TKH2' cells expressed glycophorin A (Table 4) . genitor giving rise to a cluster of 8 or more cells on day 7 , the TKH2 ' cells contained a large number of CFU-E and a small number of BFU-E, CFU-GM, CFIJ-M, and CFU-Mix (Fig 7) . In contrast with clonogenic properties ofthe T K H 2 ' cells, the TKH2-cells contained a large number of BFU-E, CFU-GM, CFU-M, and CFU-Mix.
Colon),,/i)rmation ojT'K112' BMC'. Clonogenic properties of the isolated CD2-CD19-TKH2' cells were assayed in methylcellulose culture. If we defined CFU-E as a pro-
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DISCUSSION
T and Tn antigens in most tissues are usually covered by carbohydrates, although they frequently appear in carcinoma tissues.14 Sialosyl-Tn as well as Tn has been found in erythrocyte glycophorin in Tn polyagglutinability syndrome.I5 This work suggests that premature sialosylation of GalNAc may be the major cause ofthe incomplete synthesis of 0-linked oligosaccharides in the Tn syndrome, because there is no conversion from GalNAc to Gal01 + GalNAc in the syndrome. Human erythrocyte glycophorin contains NeuActu2 -+ 3GalB I + 3(NeuActu2 + 6)GalNAc as a major 0-linked oligosaccharide." The 0-linked oligosaccharides attached to K562 leukosialin are mainly composed of
TKH2
NeuActu2 + 3GalB1 + 3(NeuActu2 -+ 6)GalNAc and its monosialylated form, NeuAce2 + 3Gal01 + 3GalNAc or Gal01 + 3(NeuAca2 -+ 6)GalNAc.l' In addition, K562 leukosialin contains GalNAc (Tn), NeuAca2 + 6GalNAc (sialosyl-Tn), and Gal@l + 3GalNAc (T) as minor components. 16 Recently, glycophorin A has been shown to contain two clusters, one with thrce (cluster I) and one with four (cluster 11) consecutive residues of GalNAc-Ser/Thr.'' Because both clusters l and I1 have T n antigenicity, the structure consisting of three consecutive glycosylated Ser/Thr residues is suggested to be essential for the Tn antigcnicity.17 Using flow cytometry and clonal cell-culture technique, WC have identified cxpression of the sialosyl-Tn antigen in erythroid cells; the antigen appeared in the range between CFU-E and erythroblasts and disappeared in erythrocytes. Several MoAbs reacting with crythroid cells have been established. SFL 23.6 reacts with CFU-E, erythroblasts, and erythrocytesi8; HH8, which identifies T-antigen, reacts with desialylated glycophorin A8; and QSH 1 and QSH2, which identify sialosyl-T antigen (GalP1 + 3(NeuAca2 -+ 6)Gal- DX  CD13  CD14  CD33  CD34  CD10  CD19  CD20  smla  CD4  CD5  CD4la  GP-A   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  2 0  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52   MO  M1  M1  M1  M2  M2  M2  M2  M2  M2  M2  M 2  M2  M3  M3  M3  M4  M4  M 4  M 4  M4  M5   M6   M6  M6  M6  L1  L1  L1  L1  L1  L1  L1  L1  L2  L2  L2  L2  L2  L3  CLL  CLL  CLL  NHL  NHL  NHL  NHL  NHL  ATL  ATL  ATL  ATL   70  42  55  34  62  58  13 repeats, and that some of these are terminated with the sialosyl-Le" structure, NeuAca2 + 3GalP1 + 4(Fucal + 3)GlcNAcfil + R, which is the ligand for E-selectin and Pselectin. They have also shown that poly-N-acetyllactosaminyl 0-glycans are absent in K562 cells and that the presence of poly-N-acetyllactosamine in 0-glycans is dependent on the core 2 fi 1,6-N-acetylglucosaminyl transferase. These results suggest that the sialytransferase enzyme creating the sialosyl-Tn antigen would compete with the core 2 GlcNAc transferase enzyme creating the lactosamine chain that bears the selectin ligand. The role of sialosyl-Tn on the stage-specific expression of erythroid cells is unclear. Because erythroblasts do not usually appear in the peripheral blood, disappearance of sialosyl-Tn may be related to release of erythrocytes from the BM into the peripheral blood.
Similar stage-specific expression of fibronectin receptor in erythroblasts has been reported. 22 We showed that sialosyl-Tn was expressed by B cells, a subset of CD4+ cells, and the transformed counterparts. The anti-sialosyl-Tn antibody, TKH2, has unique characteristics of reactivity with erythroid cells and a subset of lymphocytes. TKH:! is useful in studying erythroid differentiation and in analyzing lymphocyte populations.
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